Arrowhead Pharmaceuticals Inc., of Pasadena, Calif., earned a $25 million milestone payment from Janssen Pharmaceuticals Inc., part of New Brunswick, N.J.-based Johnson & Johnson, upon the start of dosing in a triple-combination cohort that includes JNJ-3989 (formerly ARO-HBV) in patients with chronic hepatitis B virus. The companies inked the collaboration agreement last year.